The European Commission (EC) has approved Boehringer Ingelheim’s nintedanib (brand name OFEV) for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014.
IPF is a debilitating and fatal lung disease – with a median survival of 2-3 years after diagnosis.
